Exelixis Inc. (EXEL)
Exelixis, Inc. (EXEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Exelixis, Inc. (NASDAQ:EXEL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 8:30 AM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone, and welcome to Morgan Stanley's Global Healthcare Conference. I'm Sean Laaman, Head of U.S. mid-cap biotech Equity Research here at the firm.
Exelixis, Inc. (EXEL) Presents At Citi's Biopharma Back To School Conference Transcript
Exelixis, Inc. (NASDAQ:EXEL ) Citi's Biopharma Back to School Conference September 3, 2025 3:15 PM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants David Lebowitz - Citigroup Inc., Research Division Presentation David Lebowitz Research Analyst Thank you for being here today at the 2025 Citi Biopharma Conference in Boston. Happy to have with us this afternoon.
Exelixis, Inc. (EXEL) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
Exelixis, Inc. (NASDAQ:EXEL ) 2025 Wells Fargo Healthcare Conference September 3, 2025 12:45 PM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Presentation Derek Archila Senior Equity Analyst All right, everyone. I think we'll get started here with the first session after lunch time.
Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?
The FDA approval to expand Exelixis' Cabometyx into neuroendocrine tumors is witnessing encouraging uptake and boosting investor focus.
Exelixis: RCC Stronghold, NET Launch, And A CRC Readout That Matters
CABOMETYX remains the leading TKI in renal cell carcinoma, driving strong revenue growth and expanding into new indications like neuroendocrine tumors. Exelixis's pipeline, led by zanzalintinib, shows promising Phase 3 results in colorectal cancer, offering a credible path to future revenue diversification. Financially robust with $1.4B in cash, active share buybacks, and stable commercial trends, Exelixis is well-positioned despite looming CABOMETYX exclusivity loss.
Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?
EXEL rides on Cabometyx momentum and pipeline gains, while MRK leans on Keytruda dominance and a diverse portfolio for growth.
Will EXEL's Share Repurchase Program Boost Value for Investors?
Exelixis repurchases shares for $796M, aiming to boost EPS and shareholder value through 2025.
Exelixis Gains 15.6% YTD: How Should You Play the Stock?
EXEL rides on Cabometyx growth and zanzalintinib's trial success, but Q2 revenue miss and competition keep investor sentiment cautious.
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?
Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?
EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.
Don't Overlook Exelixis (EXEL) International Revenue Trends While Assessing the Stock
Explore how Exelixis' (EXEL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
